ALK and non-small cell lung carcinoma: Since the first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib (11, 12) was introduced, the development of targeted therapy has greatly improved the survival time and quality-of- life of patients with ALK rearrangement advanced NSCLC.